AI assistant
Sending…
SELLAS Life Sciences Group, Inc. — Director's Dealing 2013
Jun 17, 2013
33651_dirs_2013-06-17_7e0fe80f-8098-4c5a-a913-e78cac796db0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-06-04
Reporting Person: SCHWARTZ MARK W. (EVP, Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-06-04 | Common Stock | A | 26110 | — | Acquired | 488798 | Direct |
Footnotes
F1: The shares acquired were issued for the account of the reporting person at a value of $2.60 per share in payment of contingent value rights held by the reporting person.
More from SELLAS Life Sciences Group, Inc.
Regulatory Filings
2026
Jun 2
Report Publication Announcement
2026
May 12
Interim / Quarterly Report
2026
May 12
Major Shareholding Notification
2026
Mar 27
Capital/Financing Update
2026
Mar 20
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9